Target intelligence / Profile preview

PcrV protein of Type III secretion system (PcrV)

Target
PcrV
Molecular classification
Translocator protein (Type III secretion system translocator), Secretion system structural protein, Needle-tip complex protein
01

Overview

The PcrV protein is an essential needle-tip component of the Type III secretion system (T3SS) in Pseudomonas aeruginosa and other Gram-negative bacteria. It functions as part of a translocator complex critical for virulence, assembling at the tip of the T3SS needle and enabling the regulated insertion of PopB and PopD proteins into host cell membranes to form a translocation pore. This pore allows direct delivery of bacterial effector proteins (toxins) into the host cytosol, manipulating host immunity and other cellular processes. PcrV plays a pivotal role in sensing host contact, orchestrating the assembly of the translocon, and triggering effector secretion. Orthologs (such as LcrV in Yersinia) also function similarly. PcrV is a validated therapeutic target; antibodies against it reduce infection severity by neutralizing pore assembly and toxin delivery, and PcrV-derived vaccines are under investigation as anti-infective agents.

Other names
Type III secretion needle tip proteinT3SS tip proteinLcrV homolog (in context of Yersinia spp. orthologs)
02

Mechanism of action

Antibodies block PcrV, impairing assembly of translocation pore and effector delivery. Inhibition of PcrV disrupts T3SS-mediated cytotoxin translocation, protecting host cells.

03

Biological functions

Assembly and regulation of Type III secretion system translocator complexMediation of effector protein translocation into host cell cytosolInteraction with PopB and PopD to form bacterial translocation poreVirulence determinant and protective antigen
04

Disease associations

Infection (primarily in Pseudomonas aeruginosa and other Gram-negative bacteria)Pathogenesis/virulence factor in bacterial diseases
05

Safety considerations

Potential immunogenicity of anti-PcrV therapies (general antibody-related reactions)Resistance development if PcrV-targeted drugs are used extensivelyT3SS is vital for virulence, but is not essential for bacterial viability (limited challenge for off-target toxicity)
06

Interacting drugs

Monoclonal antibodies (e.g., anti-PcrV antibodies, Mab166)

1 more in the full profile.

07

Biomarkers

Presence of PcrV expression as a marker for active T3SS in clinical isolatesPcrV antibodies as potential therapeutic/diagnostic markers

Beyond the preview

Go deeper on PcrV protein of Type III secretion system (PcrV).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PcrV protein of Type III secretion system (PcrV).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call